While CDK4/6 inhibitors have shown efficacy in certain cancers, there are several challenges:
1. Resistance: Tumors can develop resistance to CDK4/6 inhibitors through various mechanisms, such as mutations in CDK4/6 or activation of compensatory pathways. 2. Toxicity: Inhibiting CDK4/6 can affect normal cells, leading to side effects like neutropenia and fatigue. 3. Biomarker identification: Identifying reliable biomarkers to predict which patients will benefit from CDK4/6 inhibitors is crucial for optimizing treatment.
